| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Health Services | 10 | 2018 | 656 | 1.400 |
Why?
|
| Haiti | 28 | 2022 | 550 | 1.310 |
Why?
|
| HIV Infections | 38 | 2018 | 17328 | 1.150 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 17 | 2023 | 931 | 0.980 |
Why?
|
| Lesotho | 10 | 2024 | 74 | 0.960 |
Why?
|
| International Cooperation | 8 | 2020 | 1428 | 0.910 |
Why?
|
| Rural Population | 15 | 2022 | 2279 | 0.890 |
Why?
|
| Antitubercular Agents | 16 | 2023 | 1374 | 0.860 |
Why?
|
| Fluorine Radioisotopes | 9 | 1999 | 418 | 0.790 |
Why?
|
| Public Policy | 2 | 2022 | 559 | 0.720 |
Why?
|
| Resource Allocation | 2 | 2020 | 350 | 0.710 |
Why?
|
| Health Planning Organizations | 1 | 2019 | 13 | 0.670 |
Why?
|
| Leiomyoma | 2 | 2022 | 636 | 0.660 |
Why?
|
| Medical Assistance | 1 | 2020 | 108 | 0.660 |
Why?
|
| Organizational Objectives | 2 | 2019 | 426 | 0.630 |
Why?
|
| Monoamine Oxidase Inhibitors | 4 | 1999 | 156 | 0.620 |
Why?
|
| Delivery of Health Care | 10 | 2023 | 5332 | 0.620 |
Why?
|
| Social Support | 8 | 2016 | 2167 | 0.620 |
Why?
|
| Monoamine Oxidase | 4 | 1999 | 180 | 0.610 |
Why?
|
| Anti-HIV Agents | 13 | 2018 | 4518 | 0.610 |
Why?
|
| Health Services Accessibility | 13 | 2022 | 5421 | 0.600 |
Why?
|
| Refugees | 3 | 2022 | 595 | 0.600 |
Why?
|
| Directly Observed Therapy | 8 | 2018 | 139 | 0.590 |
Why?
|
| Developing Countries | 14 | 2020 | 2882 | 0.590 |
Why?
|
| Health Plan Implementation | 2 | 2021 | 337 | 0.580 |
Why?
|
| Primary Health Care | 5 | 2024 | 4674 | 0.560 |
Why?
|
| Population Growth | 1 | 2016 | 50 | 0.550 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2014 | 831 | 0.530 |
Why?
|
| Qualitative Research | 6 | 2024 | 3008 | 0.530 |
Why?
|
| Birth Rate | 1 | 2016 | 168 | 0.500 |
Why?
|
| Rural Health | 3 | 2006 | 296 | 0.490 |
Why?
|
| Child Mortality | 3 | 2014 | 205 | 0.490 |
Why?
|
| Human Rights | 4 | 2022 | 308 | 0.480 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2016 | 420 | 0.480 |
Why?
|
| Maternal Health Services | 2 | 2024 | 460 | 0.440 |
Why?
|
| Tomography, Emission-Computed | 11 | 1999 | 1122 | 0.430 |
Why?
|
| Communicable Disease Control | 5 | 2020 | 848 | 0.420 |
Why?
|
| Community Health Planning | 1 | 2013 | 164 | 0.420 |
Why?
|
| Caregivers | 4 | 2015 | 2232 | 0.400 |
Why?
|
| Receptors, Dopamine D2 | 5 | 1999 | 485 | 0.400 |
Why?
|
| Maternal Welfare | 1 | 2012 | 112 | 0.390 |
Why?
|
| Uterine Neoplasms | 1 | 2021 | 1420 | 0.390 |
Why?
|
| Anti-Retroviral Agents | 5 | 2012 | 1781 | 0.390 |
Why?
|
| Health Priorities | 3 | 2020 | 374 | 0.380 |
Why?
|
| Medication Adherence | 4 | 2018 | 2166 | 0.370 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2010 | 29 | 0.360 |
Why?
|
| Women's Rights | 1 | 2011 | 65 | 0.360 |
Why?
|
| Fluoxetine | 3 | 1999 | 733 | 0.350 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 3880 | 0.350 |
Why?
|
| Poverty Areas | 3 | 2006 | 264 | 0.350 |
Why?
|
| Sierra Leone | 4 | 2024 | 169 | 0.340 |
Why?
|
| HIV | 3 | 2013 | 1582 | 0.340 |
Why?
|
| Rural Health Services | 6 | 2014 | 382 | 0.340 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2011 | 1351 | 0.330 |
Why?
|
| Public Health | 1 | 2022 | 2665 | 0.310 |
Why?
|
| Civil Disorders | 1 | 2008 | 8 | 0.310 |
Why?
|
| HIV Seropositivity | 4 | 2014 | 960 | 0.300 |
Why?
|
| Harm Reduction | 1 | 2009 | 144 | 0.290 |
Why?
|
| Humans | 112 | 2024 | 760437 | 0.290 |
Why?
|
| Reproductive Medicine | 1 | 2009 | 99 | 0.290 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2010 | 2199 | 0.290 |
Why?
|
| Poverty | 10 | 2021 | 2694 | 0.280 |
Why?
|
| Blood Specimen Collection | 1 | 2008 | 238 | 0.280 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2012 | 1896 | 0.280 |
Why?
|
| Rwanda | 9 | 2018 | 665 | 0.270 |
Why?
|
| Narration | 1 | 2008 | 219 | 0.270 |
Why?
|
| Tuberculosis | 6 | 2023 | 2012 | 0.260 |
Why?
|
| Politics | 2 | 2024 | 814 | 0.260 |
Why?
|
| Adolescent Behavior | 2 | 2015 | 1186 | 0.250 |
Why?
|
| Family | 4 | 2015 | 3189 | 0.250 |
Why?
|
| Pyrrolidines | 2 | 1999 | 338 | 0.250 |
Why?
|
| Government Programs | 3 | 2019 | 279 | 0.250 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 1999 | 489 | 0.250 |
Why?
|
| Cajanus | 1 | 2024 | 2 | 0.240 |
Why?
|
| Acidosis, Lactic | 1 | 2006 | 145 | 0.240 |
Why?
|
| RNA, Plant | 1 | 2024 | 30 | 0.240 |
Why?
|
| Health Facilities | 2 | 2022 | 580 | 0.230 |
Why?
|
| Health Care Reform | 2 | 2024 | 1245 | 0.230 |
Why?
|
| World Health Organization | 3 | 2022 | 1315 | 0.230 |
Why?
|
| Family Characteristics | 1 | 2009 | 1000 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2011 | 2151 | 0.220 |
Why?
|
| Hypertension | 1 | 2024 | 8527 | 0.220 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2004 | 1191 | 0.220 |
Why?
|
| Gram-Positive Bacteria | 1 | 2004 | 178 | 0.220 |
Why?
|
| Receptors, Dopamine D1 | 2 | 1996 | 293 | 0.220 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2024 | 211 | 0.220 |
Why?
|
| Drug Approval | 1 | 2010 | 811 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 543 | 0.210 |
Why?
|
| Clorgyline | 2 | 1999 | 14 | 0.210 |
Why?
|
| Benzazepines | 2 | 1996 | 310 | 0.210 |
Why?
|
| Chlamydia Infections | 1 | 2006 | 365 | 0.210 |
Why?
|
| Vulnerable Populations | 3 | 2017 | 700 | 0.200 |
Why?
|
| Violence | 1 | 2008 | 936 | 0.200 |
Why?
|
| Depressive Disorder | 2 | 2017 | 3728 | 0.200 |
Why?
|
| Organizational Case Studies | 3 | 2020 | 301 | 0.200 |
Why?
|
| Gonorrhea | 1 | 2006 | 346 | 0.200 |
Why?
|
| Social Stigma | 3 | 2014 | 768 | 0.190 |
Why?
|
| Sexual Partners | 4 | 2010 | 795 | 0.190 |
Why?
|
| Benzamides | 2 | 1999 | 1370 | 0.190 |
Why?
|
| Women's Health | 1 | 2011 | 2065 | 0.190 |
Why?
|
| Medically Underserved Area | 1 | 2003 | 256 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 12 | 1999 | 8163 | 0.190 |
Why?
|
| Patient Compliance | 4 | 2012 | 2689 | 0.180 |
Why?
|
| National Health Programs | 2 | 2019 | 440 | 0.180 |
Why?
|
| Health Resources | 2 | 2003 | 935 | 0.170 |
Why?
|
| Interviews as Topic | 3 | 2024 | 2683 | 0.170 |
Why?
|
| Dextroamphetamine | 2 | 1997 | 134 | 0.170 |
Why?
|
| Female | 49 | 2024 | 391875 | 0.170 |
Why?
|
| Students | 1 | 2009 | 1739 | 0.170 |
Why?
|
| Malawi | 4 | 2023 | 304 | 0.170 |
Why?
|
| Depression | 5 | 2017 | 8104 | 0.170 |
Why?
|
| Radiopharmaceuticals | 2 | 1999 | 2646 | 0.160 |
Why?
|
| Health Promotion | 2 | 2011 | 2211 | 0.160 |
Why?
|
| Quality of Life | 1 | 2021 | 13338 | 0.160 |
Why?
|
| Maternal Mortality | 2 | 2012 | 301 | 0.160 |
Why?
|
| Financing, Organized | 1 | 2020 | 204 | 0.160 |
Why?
|
| Health Services Administration | 2 | 2017 | 63 | 0.160 |
Why?
|
| Uridine Monophosphate | 1 | 2018 | 68 | 0.150 |
Why?
|
| Disease Outbreaks | 4 | 2022 | 1762 | 0.150 |
Why?
|
| Earthquakes | 1 | 2021 | 190 | 0.150 |
Why?
|
| Propylamines | 1 | 1999 | 161 | 0.150 |
Why?
|
| Peru | 6 | 2008 | 890 | 0.150 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 1403 | 0.150 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 2 | 2008 | 85 | 0.150 |
Why?
|
| Health Policy | 5 | 2014 | 2680 | 0.150 |
Why?
|
| Fluorenes | 1 | 2018 | 157 | 0.150 |
Why?
|
| Consumer Advocacy | 2 | 2011 | 81 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2010 | 7817 | 0.140 |
Why?
|
| Medical Informatics | 1 | 2004 | 733 | 0.140 |
Why?
|
| Parents | 2 | 2015 | 3563 | 0.140 |
Why?
|
| Pregnancy | 9 | 2024 | 29831 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2006 | 1212 | 0.140 |
Why?
|
| House Calls | 1 | 2018 | 161 | 0.140 |
Why?
|
| Social Responsibility | 1 | 2020 | 386 | 0.140 |
Why?
|
| Health Personnel | 4 | 2024 | 3331 | 0.140 |
Why?
|
| Brain | 10 | 1999 | 27060 | 0.140 |
Why?
|
| Drug Costs | 2 | 2004 | 1179 | 0.140 |
Why?
|
| Liberia | 1 | 2016 | 174 | 0.130 |
Why?
|
| Salicylamides | 1 | 1996 | 33 | 0.130 |
Why?
|
| Male | 46 | 2024 | 360035 | 0.130 |
Why?
|
| Program Development | 3 | 2014 | 1297 | 0.130 |
Why?
|
| Rats | 12 | 1999 | 23712 | 0.130 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 2367 | 0.130 |
Why?
|
| Adult | 30 | 2024 | 220781 | 0.130 |
Why?
|
| Pandemics | 4 | 2022 | 8623 | 0.130 |
Why?
|
| Fees and Charges | 1 | 2016 | 192 | 0.130 |
Why?
|
| Program Evaluation | 7 | 2018 | 2493 | 0.130 |
Why?
|
| Financing, Government | 1 | 2019 | 472 | 0.130 |
Why?
|
| Rape | 2 | 2007 | 131 | 0.120 |
Why?
|
| Antiviral Agents | 2 | 2018 | 3066 | 0.120 |
Why?
|
| United Nations | 3 | 2011 | 150 | 0.120 |
Why?
|
| Parent-Child Relations | 2 | 2010 | 760 | 0.120 |
Why?
|
| Binding, Competitive | 4 | 1998 | 1141 | 0.120 |
Why?
|
| Education, Nursing, Diploma Programs | 1 | 2014 | 11 | 0.120 |
Why?
|
| Radioligand Assay | 4 | 1999 | 366 | 0.120 |
Why?
|
| Malnutrition | 1 | 2021 | 644 | 0.120 |
Why?
|
| Population Dynamics | 1 | 2016 | 307 | 0.120 |
Why?
|
| Social Medicine | 1 | 2015 | 64 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 2 | 2007 | 257 | 0.120 |
Why?
|
| Tissue Distribution | 5 | 1999 | 2265 | 0.120 |
Why?
|
| Macaca mulatta | 7 | 1999 | 2322 | 0.120 |
Why?
|
| Mali | 1 | 2013 | 50 | 0.110 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 26063 | 0.110 |
Why?
|
| Autoradiography | 3 | 1999 | 730 | 0.110 |
Why?
|
| Ebolavirus | 1 | 2016 | 251 | 0.110 |
Why?
|
| Retrospective Studies | 18 | 2024 | 80430 | 0.110 |
Why?
|
| Critical Illness | 2 | 2023 | 2722 | 0.110 |
Why?
|
| Adaptation, Psychological | 3 | 2015 | 2629 | 0.110 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 394 | 0.110 |
Why?
|
| Quality Improvement | 2 | 2023 | 3798 | 0.110 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 122 | 0.110 |
Why?
|
| Corpus Striatum | 2 | 1999 | 1235 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2018 | 855 | 0.110 |
Why?
|
| Learning | 1 | 2022 | 1740 | 0.110 |
Why?
|
| Internal-External Control | 1 | 2015 | 359 | 0.110 |
Why?
|
| Intensive Care Units | 2 | 2023 | 3742 | 0.110 |
Why?
|
| Hospitals | 2 | 2023 | 3873 | 0.110 |
Why?
|
| Nurse Midwives | 1 | 2012 | 23 | 0.100 |
Why?
|
| Uganda | 2 | 2008 | 1332 | 0.100 |
Why?
|
| Health Services Research | 2 | 2017 | 1811 | 0.100 |
Why?
|
| Education, Nursing | 1 | 2012 | 80 | 0.100 |
Why?
|
| Personnel, Hospital | 1 | 2014 | 285 | 0.100 |
Why?
|
| HIV Seronegativity | 2 | 2010 | 211 | 0.100 |
Why?
|
| Glycemic Index | 1 | 2014 | 395 | 0.100 |
Why?
|
| Inservice Training | 1 | 2014 | 375 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2009 | 4569 | 0.100 |
Why?
|
| Child, Orphaned | 1 | 2012 | 55 | 0.100 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 123 | 0.090 |
Why?
|
| Healthy People Programs | 1 | 2011 | 54 | 0.090 |
Why?
|
| Midwifery | 1 | 2012 | 123 | 0.090 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 494 | 0.090 |
Why?
|
| Epidemics | 1 | 2016 | 512 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2014 | 433 | 0.090 |
Why?
|
| Self-Help Groups | 1 | 2012 | 189 | 0.090 |
Why?
|
| Viral Load | 6 | 2018 | 3329 | 0.090 |
Why?
|
| Therapeutic Human Experimentation | 1 | 2010 | 43 | 0.090 |
Why?
|
| Curriculum | 2 | 2021 | 3732 | 0.090 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 1032 | 0.090 |
Why?
|
| Child, Preschool | 8 | 2022 | 42209 | 0.090 |
Why?
|
| Child Development | 1 | 2022 | 2302 | 0.090 |
Why?
|
| Occupations | 2 | 2010 | 515 | 0.090 |
Why?
|
| Research Design | 1 | 2006 | 6168 | 0.090 |
Why?
|
| Russia | 5 | 2008 | 383 | 0.080 |
Why?
|
| Adolescent | 15 | 2017 | 88196 | 0.080 |
Why?
|
| Risk Factors | 8 | 2021 | 74055 | 0.080 |
Why?
|
| Child Welfare | 1 | 2013 | 519 | 0.080 |
Why?
|
| Infant | 6 | 2022 | 36183 | 0.080 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2004 | 587 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2024 | 12785 | 0.080 |
Why?
|
| Treatment Outcome | 14 | 2018 | 64591 | 0.080 |
Why?
|
| Meningitis | 1 | 2010 | 218 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2018 | 2569 | 0.080 |
Why?
|
| Africa | 2 | 2016 | 709 | 0.080 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 3344 | 0.080 |
Why?
|
| Prevalence | 4 | 2021 | 15698 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2015 | 878 | 0.080 |
Why?
|
| Pilot Projects | 4 | 2015 | 8611 | 0.080 |
Why?
|
| Patient Dropouts | 2 | 2012 | 412 | 0.080 |
Why?
|
| Mexico | 2 | 2023 | 761 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2010 | 308 | 0.080 |
Why?
|
| Communicable Diseases | 1 | 2016 | 879 | 0.080 |
Why?
|
| Psychology | 1 | 2010 | 356 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2024 | 3796 | 0.070 |
Why?
|
| Skull | 1 | 1992 | 818 | 0.070 |
Why?
|
| Social Conditions | 1 | 2008 | 119 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 7996 | 0.070 |
Why?
|
| Nigeria | 1 | 2010 | 770 | 0.070 |
Why?
|
| Mentors | 1 | 2012 | 660 | 0.070 |
Why?
|
| Psychometrics | 1 | 2017 | 3063 | 0.070 |
Why?
|
| Telemedicine | 1 | 2024 | 3027 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 1703 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2017 | 1583 | 0.070 |
Why?
|
| Disease Management | 1 | 2017 | 2501 | 0.070 |
Why?
|
| Child | 11 | 2022 | 80086 | 0.070 |
Why?
|
| Health Status | 1 | 2020 | 4071 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 1934 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 1117 | 0.070 |
Why?
|
| HIV-1 | 5 | 2010 | 6859 | 0.070 |
Why?
|
| Boston | 3 | 2009 | 9326 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2010 | 697 | 0.070 |
Why?
|
| Dopamine Antagonists | 2 | 1997 | 288 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 7424 | 0.060 |
Why?
|
| Goals | 1 | 2011 | 711 | 0.060 |
Why?
|
| Obstetrics | 1 | 2012 | 665 | 0.060 |
Why?
|
| Algorithms | 1 | 2006 | 14002 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2010 | 554 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5835 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 940 | 0.060 |
Why?
|
| Haloperidol | 2 | 1997 | 389 | 0.060 |
Why?
|
| Capacity Building | 2 | 2020 | 258 | 0.060 |
Why?
|
| Marine Biology | 1 | 2004 | 18 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2012 | 1134 | 0.060 |
Why?
|
| Cholera | 1 | 2011 | 747 | 0.060 |
Why?
|
| Health Services | 1 | 2010 | 752 | 0.060 |
Why?
|
| Fetus | 1 | 1992 | 1863 | 0.060 |
Why?
|
| Organizations | 2 | 2016 | 171 | 0.060 |
Why?
|
| Counseling | 2 | 2010 | 1545 | 0.060 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2009 | 497 | 0.060 |
Why?
|
| Retreatment | 1 | 2006 | 598 | 0.060 |
Why?
|
| Fertility | 1 | 2009 | 771 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2015 | 2087 | 0.060 |
Why?
|
| Mothers | 1 | 2014 | 2191 | 0.060 |
Why?
|
| Seawater | 1 | 2004 | 124 | 0.060 |
Why?
|
| Professional Role | 1 | 2007 | 312 | 0.060 |
Why?
|
| Netherlands | 1 | 2008 | 2218 | 0.060 |
Why?
|
| General Surgery | 1 | 2015 | 1687 | 0.060 |
Why?
|
| Drug Industry | 1 | 2010 | 788 | 0.060 |
Why?
|
| Informed Consent | 1 | 2010 | 1006 | 0.060 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 1957 | 0.060 |
Why?
|
| Thailand | 1 | 2004 | 288 | 0.060 |
Why?
|
| Focus Groups | 2 | 2023 | 1404 | 0.060 |
Why?
|
| Drug Therapy, Combination | 4 | 2008 | 6297 | 0.060 |
Why?
|
| Disease Transmission, Infectious | 1 | 2009 | 557 | 0.050 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2004 | 99 | 0.050 |
Why?
|
| Patient Rights | 1 | 2004 | 125 | 0.050 |
Why?
|
| Education, Medical | 1 | 2015 | 1726 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2009 | 1036 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2017 | 10075 | 0.050 |
Why?
|
| Social Change | 1 | 2003 | 153 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 984 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2011 | 26280 | 0.050 |
Why?
|
| Weight Loss | 1 | 2014 | 2683 | 0.050 |
Why?
|
| Prisoners | 1 | 2006 | 314 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 3190 | 0.050 |
Why?
|
| Social Environment | 1 | 2007 | 1020 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
| Middle Aged | 15 | 2021 | 220382 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3200 | 0.050 |
Why?
|
| Interpersonal Relations | 1 | 2009 | 1436 | 0.050 |
Why?
|
| Anthropology, Cultural | 1 | 2022 | 102 | 0.050 |
Why?
|
| Linear Models | 1 | 2012 | 5865 | 0.050 |
Why?
|
| Students, Medical | 1 | 2015 | 1930 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 743 | 0.050 |
Why?
|
| Civil Rights | 1 | 2022 | 132 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 2916 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2003 | 367 | 0.050 |
Why?
|
| Antipsychotic Agents | 1 | 1995 | 3066 | 0.050 |
Why?
|
| Jordan | 1 | 2021 | 73 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2004 | 857 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2009 | 1357 | 0.050 |
Why?
|
| Logistic Models | 3 | 2012 | 13240 | 0.050 |
Why?
|
| Young Adult | 8 | 2017 | 59068 | 0.050 |
Why?
|
| Animals | 14 | 1999 | 168253 | 0.050 |
Why?
|
| Commerce | 1 | 2006 | 604 | 0.050 |
Why?
|
| Middle East | 1 | 2021 | 231 | 0.050 |
Why?
|
| Hepacivirus | 2 | 2018 | 1337 | 0.050 |
Why?
|
| Critical Care | 2 | 2023 | 2697 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2004 | 1037 | 0.040 |
Why?
|
| Pediatrics | 1 | 2015 | 3593 | 0.040 |
Why?
|
| Kinetics | 2 | 1999 | 6377 | 0.040 |
Why?
|
| Selegiline | 1 | 1999 | 32 | 0.040 |
Why?
|
| Information Systems | 1 | 2002 | 396 | 0.040 |
Why?
|
| RNA, Viral | 3 | 2018 | 2846 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 39078 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2004 | 1481 | 0.040 |
Why?
|
| Anxiety | 2 | 2015 | 4558 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2004 | 802 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2004 | 861 | 0.040 |
Why?
|
| Canada | 1 | 2004 | 2119 | 0.040 |
Why?
|
| Receptors, Dopamine D3 | 1 | 1999 | 108 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2007 | 936 | 0.040 |
Why?
|
| Synaptosomes | 1 | 1998 | 116 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2012 | 9309 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2004 | 1438 | 0.040 |
Why?
|
| Culture Techniques | 1 | 1998 | 531 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 1668 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1998 | 532 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5236 | 0.040 |
Why?
|
| Patients | 1 | 2023 | 905 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 417 | 0.040 |
Why?
|
| AIDS Vaccines | 1 | 2003 | 896 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2001 | 1766 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14661 | 0.030 |
Why?
|
| Phylogeny | 1 | 2004 | 2806 | 0.030 |
Why?
|
| Cohort Studies | 6 | 2014 | 41366 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2006 | 6340 | 0.030 |
Why?
|
| Phencyclidine | 1 | 1996 | 60 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 1379 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2022 | 22097 | 0.030 |
Why?
|
| Macaca | 1 | 1997 | 409 | 0.030 |
Why?
|
| Travel | 1 | 2022 | 795 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 1459 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 606 | 0.030 |
Why?
|
| Raclopride | 1 | 1996 | 101 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 10698 | 0.030 |
Why?
|
| Cebus | 1 | 1995 | 16 | 0.030 |
Why?
|
| Receptors, Serotonin | 1 | 1996 | 208 | 0.030 |
Why?
|
| Data Collection | 1 | 2004 | 3321 | 0.030 |
Why?
|
| Radioactive Tracers | 1 | 1995 | 66 | 0.030 |
Why?
|
| Internet | 2 | 2004 | 3092 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1998 | 959 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 1559 | 0.030 |
Why?
|
| Disasters | 1 | 2021 | 518 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2021 | 1567 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 1996 | 562 | 0.030 |
Why?
|
| Electric Injuries | 1 | 1994 | 24 | 0.030 |
Why?
|
| Needlestick Injuries | 1 | 1994 | 71 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2008 | 1912 | 0.030 |
Why?
|
| Fluconazole | 1 | 1994 | 156 | 0.030 |
Why?
|
| Molecular Structure | 2 | 1996 | 1875 | 0.030 |
Why?
|
| Health Education | 1 | 2020 | 1052 | 0.030 |
Why?
|
| Government Agencies | 1 | 2014 | 160 | 0.030 |
Why?
|
| Cryptococcosis | 1 | 1994 | 104 | 0.030 |
Why?
|
| Time Factors | 4 | 2013 | 39947 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1998 | 1956 | 0.030 |
Why?
|
| Accidents | 1 | 1994 | 165 | 0.030 |
Why?
|
| Aged | 10 | 2018 | 168840 | 0.030 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 174 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2001 | 1803 | 0.030 |
Why?
|
| Nepal | 1 | 2014 | 304 | 0.030 |
Why?
|
| Teaching | 1 | 2021 | 1169 | 0.030 |
Why?
|
| Sputum | 2 | 2008 | 506 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 1996 | 3075 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 219 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 2012 | 89 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1996 | 620 | 0.030 |
Why?
|
| Ligands | 1 | 1999 | 3270 | 0.020 |
Why?
|
| Incidence | 2 | 2011 | 21322 | 0.020 |
Why?
|
| Thiazoles | 1 | 1999 | 1513 | 0.020 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2014 | 363 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 11653 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1995 | 1540 | 0.020 |
Why?
|
| Transfection | 1 | 1999 | 5776 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2014 | 348 | 0.020 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1996 | 894 | 0.020 |
Why?
|
| Twins | 1 | 1992 | 339 | 0.020 |
Why?
|
| Fetal Death | 1 | 1992 | 435 | 0.020 |
Why?
|
| Inpatients | 1 | 2022 | 2545 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 12127 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2003 | 3240 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 601 | 0.020 |
Why?
|
| Dopamine | 1 | 1997 | 1603 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 6525 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2022 | 54339 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1994 | 1066 | 0.020 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 14565 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 5491 | 0.020 |
Why?
|
| Cerebellum | 1 | 1996 | 1500 | 0.020 |
Why?
|
| Physician Incentive Plans | 1 | 2009 | 164 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1847 | 0.020 |
Why?
|
| Social Isolation | 1 | 2010 | 364 | 0.020 |
Why?
|
| Mass Screening | 1 | 2023 | 5424 | 0.020 |
Why?
|
| Latvia | 1 | 2006 | 14 | 0.020 |
Why?
|
| Estonia | 1 | 2006 | 56 | 0.020 |
Why?
|
| Philippines | 1 | 2006 | 90 | 0.020 |
Why?
|
| Radiography | 1 | 1997 | 6963 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2003 | 1952 | 0.020 |
Why?
|
| Fear | 1 | 2014 | 1471 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 10759 | 0.020 |
Why?
|
| United States | 3 | 2021 | 72202 | 0.020 |
Why?
|
| Cell Line | 1 | 1999 | 15598 | 0.020 |
Why?
|
| Mitochondria | 1 | 1998 | 3624 | 0.020 |
Why?
|
| Leadership | 1 | 2014 | 1379 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 1918 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2017 | 2491 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 23953 | 0.010 |
Why?
|
| Diffusion of Innovation | 1 | 2009 | 726 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2017 | 2353 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6230 | 0.010 |
Why?
|
| Epitopes | 2 | 2001 | 2504 | 0.010 |
Why?
|
| Genotype | 1 | 2018 | 12976 | 0.010 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2007 | 487 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2757 | 0.010 |
Why?
|
| Perception | 1 | 2010 | 1196 | 0.010 |
Why?
|
| Body Weight | 1 | 2014 | 4614 | 0.010 |
Why?
|
| Risk | 1 | 2015 | 9605 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 1504 | 0.010 |
Why?
|
| Length of Stay | 1 | 2016 | 6413 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5283 | 0.010 |
Why?
|
| Information Management | 1 | 2002 | 100 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 8967 | 0.010 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2003 | 266 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2001 | 211 | 0.010 |
Why?
|
| Gene Products, gag | 1 | 2001 | 312 | 0.010 |
Why?
|
| HIV Antigens | 1 | 2001 | 325 | 0.010 |
Why?
|
| Acute Disease | 2 | 2001 | 7230 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 206 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 1087 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 13445 | 0.010 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2005 | 662 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 20078 | 0.010 |
Why?
|
| Public Health Practice | 1 | 2001 | 219 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 4849 | 0.010 |
Why?
|
| Comorbidity | 1 | 2012 | 10494 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2007 | 1416 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2008 | 2771 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 2820 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8522 | 0.010 |
Why?
|
| Dizocilpine Maleate | 1 | 1996 | 172 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2002 | 961 | 0.010 |
Why?
|
| Genetic Variation | 2 | 2001 | 6570 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2001 | 973 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1996 | 462 | 0.010 |
Why?
|
| Isotope Labeling | 1 | 1996 | 393 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1994 | 129 | 0.010 |
Why?
|
| Research | 1 | 2002 | 1977 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 12429 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12054 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 3685 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12449 | 0.010 |
Why?
|
| Muscles | 1 | 1994 | 1575 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 9046 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 17639 | 0.000 |
Why?
|
| Age Factors | 1 | 2005 | 18379 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 58859 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1996 | 3765 | 0.000 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 7380 | 0.000 |
Why?
|